Stock Events

Cara Therapeutics 

$0.34
70
+$0.06+22.74% Today

Statistics

Day High
-
Day Low
-
52W High
4.45
52W Low
0.24
Volume
2,104,616
Avg. Volume
1,060,403
Mkt Cap
18.59M
P/E Ratio
-0.15
Dividend Yield
-
Dividend
-

Earnings

13MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.59
-0.5
-0.41
-0.32
Expected EPS
-0.4
Actual EPS
-0.56

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CARA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap120.95B
Vertex Pharmaceuticals is involved in creating treatments for pain management, directly competing with Cara Therapeutics' focus on novel pain therapies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.21B
Teva Pharmaceutical Industries has a broad portfolio that includes pain management solutions, making it a competitor in the same therapeutic area as Cara Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap357.99B
Johnson & Johnson, through its pharmaceutical segment, develops drugs for various conditions including pain, competing with Cara Therapeutics' pain management products.
Abbvie
ABBV
Mkt Cap300.89B
AbbVie has a strong presence in the pain management market with its portfolio of analgesics, competing with Cara Therapeutics.
Pfizer
PFE
Mkt Cap157.19B
Pfizer has a diverse drug portfolio that includes pain management medications, positioning it as a competitor to Cara Therapeutics.
Novartis
NVS
Mkt Cap230.42B
Novartis AG offers a range of pain management solutions, making it a direct competitor in the therapeutic area that Cara Therapeutics targets.
Merck &
MRK
Mkt Cap331.09B
Merck & Co., Inc. develops medications for various therapeutic areas, including pain, competing with Cara Therapeutics' focus.
Gilead Sciences
GILD
Mkt Cap88.04B
Gilead Sciences, though primarily known for antiviral drugs, has ventured into other therapeutic areas, including pain management, competing with Cara Therapeutics.
Alkermes
ALKS
Mkt Cap4.15B
Alkermes plc works on central nervous system (CNS) disorders, including treatments for pain, positioning it as a competitor to Cara Therapeutics.

Analyst Ratings

1$Average Price Target
The highest estimate is $1.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Show more...
CEO
Derek Chalmers
Employees
55
Country
US
ISIN
US1407551092
WKN
000A1XDTK

Listings